AgonOx, Inc.

Quick facts

Phase 1 pipeline

• DP CD8 TIL
• DP CD8 TIL KD
  CD8+ tumor-infiltrating lymphocytes engineered or selected to recognize and attack cancer cells within the tumor microenvironment.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• AgonOx, Inc. portfolio CI brief
• AgonOx, Inc. pipeline updates RSS

Related

• Sector hub: All tracked pharma companies